TG Therapeutics Q1 revenue rises, lifts 2026 outlook

TG Therapeutics

06/05/2026 12:14

Overview

US biotech firm's Q1 product revenue rose yr/yr, driven by BRIUMVI sales

Q1 net income increased to $19.8 mln from $5.1 mln a year ago

Company raised 2026 global revenue and BRIUMVI U.S. sales guidance

Outlook

TG Therapeutics raises 2026 total global revenue target to $925 mln

Company raises 2026 BRIUMVI U.S. net product revenue target to $885-900 mln

TG Therapeutics targets Q2 2026 BRIUMVI U.S. net product revenue at $220 mln

Result Drivers

BRIUMVI DEMAND - Co said growth was driven by strong underlying demand, record new patient starts, and consistent commercial execution for BRIUMVI

COMMERCIALIZATION COSTS - Higher SG&A expenses were primarily due to increased marketing, media spend, and personnel costs related to BRIUMVI commercialization

R&D EXPENSES - R&D costs increased due to license and milestone expenses, clinical trial activity, and higher personnel costs

Company press release: ID:nGNX9Gx96D

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Product Revenue
$201.31 mln
Q1 EPS
$0.12
Q1 Net Income
$19.78 mln
Q1 Operating Income
$34.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for TG Therapeutics Inc is $48.00, about 33% above its May 5 closing price of $36.10

The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 17 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)